



Cosmo receives positive EMA CHMP Opinion recommending approval of Methylene Blue MMX for the visualization of colorectal lesions during colonoscopies

Dublin, Ireland - June 26, 2020. Cosmo Pharmaceuticals NV (SIX: COPN) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Methilthionium Chloride Cosmo (Methylene Blue MMX), its drug for the visualization of colorectal lesions during colonoscopies.

The CHMP recommendation will now be reviewed by the European Commission, which has the authority to approve medicines centrally for the European Union. Access to the centralised procedure had been granted to Methylene Blue MMX on the grounds of its significant innovation and interest for patients. The final decision on the Marketing Authorisation Application for Methylene Blue MMX is expected in the next couple of months. The granting of a centralised European licence will be effective simultaneously in all EU Member States as well as in the European Economic Area (EEA) countries Iceland, Liechtenstein and Norway.

Alessandro Della Chà, CEO of Cosmo, said: *"This positive CHMP opinion is great news for Cosmo. It confirms that Methylene Blue MMX has the potential to become an important aid during colonoscopies for the visualization of those 'easy to miss' lesions and to enhance the overall performance of endoscopists by increasing their Adenoma Detection Rate."*

Mauro Ajani, Chairman of Cosmo, said: *"The positive recommendation for Methylene Blue MMX by the EMA is a very significant achievement for Cosmo and a great advancement in the fight against colorectal cancer. I wish to thank all those that helped Cosmo get to this point."*

The CHMP adopted the positive opinion based on the data stemming from the single phase III trial performed by Cosmo worldwide in 20 sites involving 1249 randomised patients. The study was powered to show a statistically significant difference between Methylene blue MMX 200 mg and placebo (corresponding to High-Definition White Light [HDWL] colonoscopy – the current standard of care) in the detection of patients with at least one adenoma or carcinoma (Adenoma Detection Rate [ADR]). The study met its prespecified endpoint: the ADR was higher in the Methylene Blue MMX arm as compared to HDWL colonoscopy (56.29% vs 47.81%, respectively; difference: 8.48%; RRI 17.7%; OR [95% CI]: 1.41 [1.09, 1.81]; p-value: 0.0099).

Important prespecified secondary endpoints showed that Methylene Blue MMX increases the detection of patients with at least one adenoma and does not produce an increase in the False Positive Rate (FPR) as compared to HDWL colonoscopy. Additional endpoints showed that Methylene Blue MMX increases, in particular, detection of non-polypoid (flat) lesions (the most frequently missed lesions).

Based on the benefits of Methylene Blue MMX in terms of increase in ADR and on the lack of major safety issues, the CHMP adopted a positive benefit/risk balance.

The indication of Methylene Blue MMX recommended for approval by the CHMP is as a “*diagnostic agent enhancing visualization of colorectal lesions in adult patients undergoing screening or surveillance colonoscopy*”.

About Cosmo Pharmaceuticals

Cosmo is a specialty pharmaceutical company focused on developing and commercialising products to treat selected gastrointestinal disorders and improve endoscopy quality measures through aiding the detection of colonic lesions. Cosmo has also developed medical devices for endoscopy and has recently entered into a partnership with Medtronic for the global distribution of GI Genius™ its artificial intelligence device for use in colonoscopies and GI procedures. Cosmo has licensed Aemcolo™ to Red Hill Biopharma and is the licensee of Byfavo™ (Remimazolam) for the U.S. for procedural sedation, which it has sub-licensed to Acacia. For additional information on Cosmo and its products please visit the Company’s website: www.cosmopharma.com

Financial calendar

2020 Half-Year Results

July 30, 2020

Contact

Niall Donnelly, CFO & Head of Investor Relations

Cosmo Pharmaceuticals N.V.

Tel: +353 1 817 03 70

ndonnelly@cosmopharma.com

Disclaimer

Some of the information contained in this press release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. Cosmo undertakes no obligation to publicly update or revise any forward-looking statements.

This communication is not an offer of securities of any issuer. Securities may not be offered or sold in the United States absent registration or an exemption from the registration requirement of the US Securities Act of 1933.

This press release constitutes neither an offer to sell nor a solicitation to buy securities and it does not constitute a prospectus within the meaning of article 652a and/or 1156 of the Swiss Code of Obligations or a listing prospectus within the meaning of the listing rules of the SIX Swiss Exchange or any similar document. The offer will be made solely by means of, and on the basis of, a securities prospectus to be published. An investment decision regarding the securities to be publicly offered should only be made on the basis of the securities prospectus.

This press release is made to and directed only at (i) persons outside the United Kingdom, (ii) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”), and (iii) high net worth individuals, and other persons to whom it may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order. Any person who is not a relevant person should not act or rely on this press release or any of its contents.

This press release does not constitute an “offer of securities to the public” within the meaning of Directive 2003/71/EC of the European Union (the “Prospectus Directive”) of the securities referred to in it (the “Securities”) in any member state of the European Economic Area (the “EEA”). Any offers of the Securities to persons in the EEA will be made pursuant to an exemption under the Prospectus Directive, as implemented in member states of the EEA, from the requirement to produce a prospectus for offers of the Securities.